首页> 外文期刊>Bone marrow transplantation >Therapeutic choices in patients with Ph-positive CML living in Mexico in the tyrosine kinase inhibitor era: SCT or TKIs?
【24h】

Therapeutic choices in patients with Ph-positive CML living in Mexico in the tyrosine kinase inhibitor era: SCT or TKIs?

机译:酪氨酸激酶抑制剂时代居住在墨西哥的Ph阳性CML患者的治疗选择:SCT还是TKI?

获取原文
获取原文并翻译 | 示例
       

摘要

A total of 72 patients with Ph-positive CML in first chronic phase were followed during a 6-year period in two different institutions in Mexico. Among them, 22 were given a reduced-intensity allogeneic SCT, whereas 50 were given a tyrosine kinase inhibitor (TKI), mainly imatinib mesylate. The 6-year overall survival (OS) after the therapeutic intervention for patients allografted or given a TKI was 77 and 84%, respectively (P, NS); the median OS for both groups has not been reached, being above 90 and 71 months, respectively (P, NS). The freedom from progression to blast or accelerated phases was also similar for both groups, as well as the overall OS after diagnosis. Most patients allografted (91%) chose this treatment because they were unable to afford continuing treatment with the TKI, whereas most treated with the TKI (84%) were given the treatment without charge, through institutions able to pay for their treatment. The median cost of each nonmyeloablative allograft was USDollars 18,000, an amountthat is enough to cover 180 days of treatment with imatinib (400 mg per day) in Mexico. Cost considerations favor allogeneic SCT as a 'once only' procedure whereas lifelong treatment with an expensive drug represents an excessive burden on resources.
机译:在墨西哥的两个不同机构进行的为期6年的随访中,总共对72位第一慢性期Ph阳性CML患者进行了随访。其中22例接受了强度降低的异基因SCT,而50例接受了酪氨酸激酶抑制剂(TKI),主要是甲磺酸伊马替尼。同种异体移植或TKI患者进行治疗干预后的6年总生存率分别为77%和84%(P,NS);两组的中位OS均未达到,分别超过90和71个月(P,NS)。两组从进展到爆炸或加速阶段的自由度以及诊断后的总体OS也相似。同种异体移植的大多数患者(91%)之所以选择这种治疗方法,是因为他们无法负担继续使用TKI进行治疗的费用,而大多数接受TKI治疗的患者(84%)是通过有能力为其治疗付费的机构免费提供治疗的。每次非清髓性同种异体移植术的中位数成本为18,000美元美元,足以覆盖墨西哥180天伊马替尼(每天400毫克)的治疗费用。成本方面的考虑将异基因SCT视为“仅一次”手术,而终身使用昂贵的药物治疗会给资源带来过多负担。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号